Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Investor Presentation November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Press Releases
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
press release
January 15, 2020
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned…
Read moreObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of China
press release
January 13, 2020
Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a…
Read moreObsEva SA to Participate in JP Morgan Healthcare Conference January 13-16, 2020
press release
January 7, 2020
Geneva, Switzerland and Boston, MA – January 7, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
1 2 Next »Stock Information
Latest Press Release
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Media United States
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Contacts
Media Switzerland & Europe
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Media United States
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Sign up for news
